Cargando…
COVID-19 and VITT: same or different?
Autor principal: | Arepally, Gowthami M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496344/ https://www.ncbi.nlm.nih.gov/pubmed/34618003 http://dx.doi.org/10.1182/blood.2021013362 |
Ejemplares similares
-
Second-dose VITT: rare but real
por: Pavord, Sue, et al.
Publicado: (2022) -
A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination
por: Handtke, Stefan, et al.
Publicado: (2021) -
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
por: Greinacher, Andreas, et al.
Publicado: (2021) -
Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic?
por: Sarkar, Amrita, et al.
Publicado: (2023) -
Targeting complement activation in COVID-19
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2020)